Dr. Zhengqing Li, an Experienced China Pharma Exec, Joins Ascletis
publication date: Mar 13, 2019
Dr. Zhengqing Li recently joined Ascletis, a Hangzhou company focused on therapeutic areas including anti-viral, cancer and fatty liver diseases, as Chief Medical Officer and President of R&D Greater China. Prior to Ascletis, Dr. Li worked at MSD China from 2011 to last month, where he served as Global Vice President and General Manager of the MSD R&D Center China. During his tenure, he built MSD China into a fully integrated development organization with more than 600 employees that led more than 20 product or new indication approvals in China. In an exclusive interview, Dr. Li spoke with ChinaBio® Today, discussing his path and what's next for Ascletis. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.